CN109069502A - 含盐皮质激素受体拮抗剂的药物组合物及其用途 - Google Patents

含盐皮质激素受体拮抗剂的药物组合物及其用途 Download PDF

Info

Publication number
CN109069502A
CN109069502A CN201780006183.XA CN201780006183A CN109069502A CN 109069502 A CN109069502 A CN 109069502A CN 201780006183 A CN201780006183 A CN 201780006183A CN 109069502 A CN109069502 A CN 109069502A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
daily dose
optionally
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780006183.XA
Other languages
English (en)
Other versions
CN109069502B (zh
Inventor
黄振华
郭小翠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
KBP Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KBP Biosciences Co Ltd filed Critical KBP Biosciences Co Ltd
Publication of CN109069502A publication Critical patent/CN109069502A/zh
Application granted granted Critical
Publication of CN109069502B publication Critical patent/CN109069502B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

一种含盐皮质激素受体拮抗剂的药物组合物及其用途。药物组合物口服给药于需要其治疗的慢性肾病患者，其有效且安全的AUC范围为188ng*h/mL至3173ng*h/mL，其在哺乳动物中的生物利用度≥50％。药物组合物以日剂量为0.1mg‑1.0mg给药用于治疗慢性肾病时AUC控制在安全有效的范围内。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201780006183.XA 2016-09-24 2017-09-22 含盐皮质激素受体拮抗剂的药物组合物及其用途 Active CN109069502B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108491424 2016-09-24
CN201610849142 2016-09-24
PCT/CN2017/102969 WO2018054357A1 (zh) 2016-09-24 2017-09-22 含盐皮质激素受体拮抗剂的药物组合物及其用途

Publications (2)

Publication Number Publication Date
CN109069502A true CN109069502A (zh) 2018-12-21
CN109069502B CN109069502B (zh) 2021-08-06

Family

ID=61689352

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780006183.XA Active CN109069502B (zh) 2016-09-24 2017-09-22 含盐皮质激素受体拮抗剂的药物组合物及其用途

Country Status (30)

Country Link
US (2) US11806344B2 (zh)
EP (1) EP3517113A4 (zh)
JP (2) JP7090599B2 (zh)
KR (1) KR102226516B1 (zh)
CN (1) CN109069502B (zh)
AU (1) AU2017329549B2 (zh)
BR (1) BR112019005214A2 (zh)
CA (1) CA3037588C (zh)
CL (1) CL2019000753A1 (zh)
CO (1) CO2019003808A2 (zh)
CR (1) CR20190203A (zh)
CU (1) CU24569B1 (zh)
DO (1) DOP2019000072A (zh)
EA (1) EA201990668A1 (zh)
EC (1) ECSP19027578A (zh)
HK (1) HK1258622A1 (zh)
IL (1) IL265560B (zh)
MA (1) MA45202B1 (zh)
MX (1) MX2019003339A (zh)
MY (1) MY195054A (zh)
NZ (1) NZ751901A (zh)
PE (1) PE20190608A1 (zh)
PH (1) PH12019500516A1 (zh)
RU (2) RU2750667C2 (zh)
SG (1) SG10201912389WA (zh)
TN (1) TN2019000063A1 (zh)
TW (2) TWI780488B (zh)
UA (1) UA123464C2 (zh)
WO (1) WO2018054357A1 (zh)
ZA (1) ZA201901740B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492336A (zh) * 2023-04-04 2023-07-28 迪沙药业集团有限公司 一种坎地沙坦酯药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069502B (zh) 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
CN113425683B (zh) * 2021-08-19 2022-09-20 谢彩华 一种三氮脒缓释注射剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022121A1 (zh) * 2010-08-18 2012-02-23 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2014094664A1 (zh) * 2012-12-22 2014-06-26 山东亨利医药科技有限责任公司 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
EP3251660B1 (en) * 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
HUE034890T2 (hu) * 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Malononitrilaminok alkalmazása neuropathiás fájdalomban
CN109069502B (zh) 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022121A1 (zh) * 2010-08-18 2012-02-23 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2014094664A1 (zh) * 2012-12-22 2014-06-26 山东亨利医药科技有限责任公司 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492336A (zh) * 2023-04-04 2023-07-28 迪沙药业集团有限公司 一种坎地沙坦酯药物组合物

Also Published As

Publication number Publication date
TWI780488B (zh) 2022-10-11
EA201990668A1 (ru) 2019-10-31
TN2019000063A1 (en) 2020-07-15
IL265560B (en) 2022-07-01
SG10201912389WA (en) 2020-02-27
RU2020120876A (ru) 2020-08-26
AU2017329549B2 (en) 2020-05-14
NZ751901A (en) 2021-07-30
MA45202A1 (fr) 2020-11-30
JP2022037044A (ja) 2022-03-08
DOP2019000072A (es) 2019-06-16
EP3517113A1 (en) 2019-07-31
CN109069502B (zh) 2021-08-06
MA45202B1 (fr) 2022-04-29
KR102226516B1 (ko) 2021-03-12
US20190201390A1 (en) 2019-07-04
CA3037588C (en) 2022-07-12
MX2019003339A (es) 2019-06-03
BR112019005214A2 (pt) 2019-06-11
JP7090599B2 (ja) 2022-06-24
IL265560A (en) 2019-05-30
PH12019500516A1 (en) 2020-02-24
AU2017329549A1 (en) 2019-04-11
ZA201901740B (en) 2019-10-30
CA3037588A1 (en) 2018-03-29
UA123464C2 (uk) 2021-04-07
MY195054A (en) 2023-01-05
TW201813645A (zh) 2018-04-16
RU2725153C1 (ru) 2020-06-30
CL2019000753A1 (es) 2019-07-19
RU2020120876A3 (zh) 2020-12-28
TW202100156A (zh) 2021-01-01
US20240016796A1 (en) 2024-01-18
TWI715806B (zh) 2021-01-11
JP2019532939A (ja) 2019-11-14
KR20190057323A (ko) 2019-05-28
HK1258622A1 (zh) 2019-11-15
EP3517113A4 (en) 2020-07-08
WO2018054357A1 (zh) 2018-03-29
PE20190608A1 (es) 2019-04-23
CO2019003808A2 (es) 2019-04-30
CU24569B1 (es) 2022-01-13
US11806344B2 (en) 2023-11-07
CU20190023A7 (es) 2019-11-04
RU2750667C2 (ru) 2021-06-30
ECSP19027578A (es) 2019-07-31
CR20190203A (es) 2019-06-26

Similar Documents

Publication Publication Date Title
JP2022037044A (ja) ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
AU2010315362B2 (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2008016115A (es) Composiciones que comprenden meloxicam nanoparticulado e hidrocodona de liberacion controlada.
UA123856C2 (uk) Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
TW201113050A (en) 3-cyanoquinoline tablet formulations and uses thereof
AU2010242938A1 (en) Fixed dose drug combination formulations
JP2012530127A (ja) ナノ粒子のカンデサルタンシレキセチル組成物、その調製方法及びそれらを含有する医薬組成物
US20150342882A1 (en) Methods of treatment using cadotril compositions
CN101653440B (zh) 含有氨氯地平系列盐和普利类药物的治疗组合物
KR20200080271A (ko) 알파-폴리글루탐산-아연을 포함하는 암 치료용 조성물
CN104324377B (zh) 一种复方降压制剂及其应用
WO2011027021A1 (en) A method for the treatment of hypertension
CN101491519A (zh) 一种银杏内酯注射剂及其制备方法
CN113521292A (zh) 一种cox-2抑制剂和曲马多的复方制剂
EA041410B1 (ru) Применение антагониста минералокортикоидных рецепторов для лечения хронической болезни почек и способ лечения хронической болезни почек
BR102013026288B1 (pt) Composição farmacêutica com um anti-hipertensivo e um diurético
WO2005032516A1 (en) Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258622

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221114

Address after: 80 ROBINSON ROAD, SINGAPORE # 02-00

Patentee after: KBP Pharmaceutical Technology Singapore

Address before: 250101 Room 401, building 2, Jinan Yaogu, north section of Gangxing Third Road, high tech Zone, Jinan City, Shandong Province

Patentee before: KBP BIOSCIENCES Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240220

Address after: Denmark bagsvaerd

Patentee after: NOVO NORDISK A/S

Country or region after: Denmark

Address before: 80 Robinson Road, Singapore # 02-00

Patentee before: KBP Pharmaceutical Technology Singapore

Country or region before: Singapore